Indian pharma companies unfazed by US slowdown fears

Published on Tue, Feb 19, 2008 at 08:53 |  Source : CNBC-TV18

Updated at Tue, Feb 19, 2008 at 15:15  

11997 Investors following Piramal Holding. Share this News with them.
0
0
Share on Tumblr
Power Breakfast

Excerpts from Power Breakfast on CNBC-TV18 Watch the full show »

ALSO READ

Other Stocks in this news

Ranbaxy Laboratories | Unichem Laboratories |

The Indian stock market may be dreading a possible US recession but Indian pharma companies seem unfazed by slowdown fears, reports CNBC-TV18's Vikas Dandekar.

 

Nicholas Piramal chairman Ajay Piramal has grown his custom research and manufacturing business in the last four years from zero to around USD 300 million, that's more than half of his company's total sales of USD 550 million last year.

 

Custom manufacturing depends mostly on scientific research and manufacturing work dished out by multinational drug makers to low cost drug manufacturers. A majority of Nicholas Piramal's custom manufacturing revenues currently come from Pfizer and even as US drug makers look for cost efficiencies due to a likely slowdown, that number will keep growing. That's not just for Nicholas Piramal but also similar Indian companies.

 

Ever hungry for strategic acquisitions, Ajay Piramal says now with valuations reaching reasonable levels due to recession fears, acquisitions of American assets may also be looked at in the US. A similar optimism is expressed by Unichem's Dr Prakash Mody . Unichem is a late entrant in the US generics market and has only about 10 products in that market. Dr Mody says with bigger generic companies experiencing an unprecedented price erosion, the benefits of switching from branded products of multinationals to generics may now accrue to smaller Indian companies.

 

Even large generic companies like Ranbaxy feel that reduced margins from the US market is already factored in and a strategy to shift from generics to branded generics should help shore up profit margins in the US. So, as contract research and manufacturing and big and small generic players are not expecting to be hit by a possible slowdown, the Indian drug industry seems prepared to do well in adverse conditions.

  

More on Moneycontrol

Trending News

Business News

Samsung Galaxy mini 2 S6500 promo picture leaked
Rupee rally may stall with fall against US dollar, euro "Rupee rally may stall with fall against US dollar, euro"

CNBC-TV18 ALERT FIPB: Foreign Investment Promotion Board

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Feb 10 2012, 15:35 | Source: CNBC-TV18

Expect Q4 GRMs to be similar to Q3: BPCL  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com